# Insulet Corporation  Share Price Target ‘$236.83’, now 39.1% Upside Potential

- Link: https://www.directorstalkinterviews.com/insulet-corporation-share-price-target-236.83-now-39.1-upside-potential/4121154324
- Published: 2024-05-01T14:25:33+01:00
- Author: Charlotte Edwards

**Insulet Corporation** which can be found using ticker (PODD) have now 18 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The target
price High/Low ranges between $270.00 and $208.00 suggesting an average analyst 
share price target price of $236.83. (at the time of writing). Now with the previous
closing price of $170.26 and the analysts are correct then there would likely be
a percentage uptick in value of 39.1%. The 50 day moving average now sits at $171.10
and the 200 day MA is $187.29. The market cap for the company is 12.04B. The stock
price for the company is currently $171.94 USD

 The potential market cap would be $16,747,060,403 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 58.48, revenue per share of $24.33
and a 6.09% return on assets.

Insulet Corporation is primarily engaged in the development, manufacture and sale
of its Omnipod System, a continuous insulin delivery system for people with insulin-
dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System(
Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and
the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System 
features a small, lightweight, self-adhesive disposable tubeless Omnipod device (
Pod) that the user fills with insulin and wears directly on the body for up to three
days at a time, which delivers personalized doses of insulin, and the Personal Diabetes
Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with
the user’s personalized insulin-delivery instructions and wirelessly monitors the
Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta
Onpro kit, a delivery system for Amgen’s Neulasta.

Share on: